SMMT vs. MRK, TAK, ARGX, ONC, INSM, BNTX, TEVA, GMAB, VTRS, and ASND
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Merck & Co., Inc. (MRK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "medical" sector.
Summit Therapeutics vs. Its Competitors
Merck & Co., Inc. (NYSE:MRK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.
Merck & Co., Inc. has a net margin of 25.79% compared to Summit Therapeutics' net margin of 0.00%. Merck & Co., Inc.'s return on equity of 41.05% beat Summit Therapeutics' return on equity.
Merck & Co., Inc. has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the S&P 500.
Merck & Co., Inc. presently has a consensus price target of $107.44, suggesting a potential upside of 27.59%. Summit Therapeutics has a consensus price target of $33.31, suggesting a potential upside of 41.61%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Merck & Co., Inc..
In the previous week, Merck & Co., Inc. had 49 more articles in the media than Summit Therapeutics. MarketBeat recorded 64 mentions for Merck & Co., Inc. and 15 mentions for Summit Therapeutics. Merck & Co., Inc.'s average media sentiment score of 1.32 beat Summit Therapeutics' score of 0.90 indicating that Merck & Co., Inc. is being referred to more favorably in the media.
76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 0.1% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Merck & Co., Inc. has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.
Summary
Merck & Co., Inc. beats Summit Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SMMT) was last updated on 9/4/2025 by MarketBeat.com Staff
